Walleye Capital’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.41M Buy
+149,707
New +$3.44M ﹤0.01% 2639
2026
Q1
– Sell
-27,762
Closed -$543K – 4533
2025
Q4
$543K Buy
+27,762
New +$526K ﹤0.01% 2911
2025
Q2
– Sell
-154,634
Closed -$1.62M – 4615
2025
Q1
$1.62M Buy
+154,634
New +$2.21M 0.01% 1586
2024
Q3
– Sell
-85,652
Closed -$3.02M – 5414
2024
Q2
$3.02M Buy
+85,652
New +$2.49M 0.01% 1718
2023
Q4
– Sell
-280,276
Closed -$2.51M – 5074
2023
Q3
$2.51M Buy
+280,276
New +$3.02M 0.01% 1553
2021
Q2
– Sell
-20,000
Closed -$311K – 1384
2021
Q1
$311K Buy
+20,000
New +$387K 0.02% 738

Other funds holding DYN

Walleye Capital's DYN Position: Q3 2026 in Review

Walleye Capital opened a new position in Dyne Therapeutics (DYN) in Q3 2026: 149,707 shares worth $2.41M. The stake represents ﹤0.01% of the portfolio and ranks #2639 among its holdings. This is a return to the name: Walleye Capital previously reported a position in DYN as recently as Q4 2025.

Walleye Capital first reported a position in DYN in Q1 2021 and has held it in 6 quarters since. The position peaked at $3.02M in Q2 2024. 270 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Walleye Capital held 149,707 shares of Dyne Therapeutics worth $2.41M as of Q3 2026.
  • Dyne Therapeutics was a new Walleye Capital position in Q3 2026.
  • Dyne Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2639 holding.
  • Walleye Capital first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Walleye Capital's Dyne Therapeutics position peaked at $3.02M in Q2 2024.
  • 270 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.